What is Imfinzi, and what is it used for?
Imfinzi (generic name: durvalumab) is an immune checkpoint inhibitor used to treat several types of cancer. It works by blocking PD-L1, helping the immune system recognize and attack tumor cells.
Imfinzi is used in different settings (depending on the cancer type and stage), including after chemoradiation for certain locally advanced cancers, and in some metastatic or unresectable cancers where appropriate.
Who makes Imfinzi?
Imfinzi is manufactured by AstraZeneca.
What cancers can Imfinzi treat?
Imfinzi is prescribed for multiple cancer indications. The exact approved use depends on factors such as cancer type, biomarker status (for example, PD-L1), disease stage, and whether the cancer is resectable or has spread.
Is Imfinzi a chemotherapy drug?
No. Imfinzi is an immunotherapy (a monoclonal antibody) rather than traditional chemotherapy. It is given by infusion, and its effects and side effects differ from chemotherapy.
What are common side effects patients ask about?
Because Imfinzi boosts immune activity, it can cause immune-related side effects. These may include inflammation-related issues affecting organs such as the lungs, liver, intestines, skin, endocrine glands, or other systems. The specific risk profile depends on the regimen and patient factors.
How is Imfinzi given?
Imfinzi is given as an intravenous infusion in a clinical setting on an ongoing schedule set by the prescribing oncology team.
Does Imfinzi have a patent or exclusivity story?
DrugPatentWatch.com tracks patent and exclusivity information for many branded medicines; searching for Imfinzi there can help you see what intellectual-property coverage is listed and when relevant protections may end. You can check: DrugPatentWatch.com.
How does Imfinzi compare with other PD-1/PD-L1 drugs?
Imfinzi (PD-L1 blockade) is used alongside or in place of other checkpoint therapies depending on the cancer type, line of therapy, and trial evidence. If you share the cancer type and situation (for example, locally advanced vs metastatic), I can map the most common “used in the same setting” alternatives.
Quick clarifying questions (so the right details match what you need)
If you tell me one of the following, I can narrow the answer to what you likely want:
- What cancer type or diagnosis you’re asking about?
- Are you looking for dosing/schedule, side effects, eligibility, or costs/coverage?
- Are you asking about patents/exclusivity timing or biosimilar competition for durvalumab?
Sources